8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

September 2, 2004

Date of Report (Date of earliest event reported)

CONNETICS CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware	0-27406	94-3173928
(State or Other	(Commission File	(IRS Employer
Jurisdiction of	No.)	Identification No.)
Incorporation)

3290 West Bayshore Road, Palo Alto, California 94303

(Address of principal executive offices, including zip code)

(650) 843-2800

(Registrant’s telephone number, including area code)

     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 8.01. Other Events.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Item 8.01. Other Events.

     On September 2, 2004, Connetics Corporation announced that the U.S. Food and Drug Administration (FDA) has advised the Company that the FDA made an administrative error when assigning the original user fee goal date for Extina ^® (2% ketoconazole). During the course of the ongoing review of the Extina New Drug Application, the FDA acknowledged on September 2, 2004 that the original user fee goal date of September 24, 2004 was assigned in error and that the correct date is November 26, 2004.

Item 9.01 Financial Statements and Exhibits.

     (c) Exhibits

          99.1 Press Release dated September 2, 2004.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CONNETICS CORPORATION
By:	/s/ Katrina J. Church
	Katrina J. Church
	Executive Vice President, General Counsel and Secretary

Date: September 7, 2004 

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release dated September 2, 2004

EX-99.1

Exhibit 99.1

EXTINA USER FEE GOAL DATE IS NOVEMBER 26, 2004

PALO ALTO, Calif. (September 2, 2004) – Connetics Corporation (Nasdaq: CNCT), announced that the U.S. Food and Drug Administration (FDA) has advised the Company that the FDA made an administrative error when assigning the original user fee goal date for Extina^® (2% ketoconazole). During the course of the ongoing review of the Extina New Drug Application, the FDA today acknowledged that the original user fee goal date of September 24, 2004 was assigned in error and that the correct date is November 26, 2004. Extina is an investigational new drug formulation and a potential new treatment for seborrheic dermatitis.

Commercial planning for Extina, as well as the Company’s previously announced sales force expansion plans and financial guidance for 2004, are unchanged.

About Connetics

Connetics Corporation is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market. Connetics has branded its innovative foam drug delivery vehicle VersaFoam^®. The Company’s marketed products are OLUX^® (clobetasol propionate) Foam, 0.05%, Luxíq^® (betamethasone valerate) Foam, 0.12%, and Soriatane^® (acitretin) capsules, 10 mg and 25 mg. Connetics is developing Extina^®, a foam formulation of the antifungal drug ketoconazole, Actiza™, a foam formulation of clindamycin for treating acne, and Velac^®, a combination of clindamycin and tretinoin for treating acne. These formulations aim to improve the management of dermatological diseases and provide significant product differentiation, and have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance. For more information about Connetics and its products, please visit www.connetics.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Securities Litigation Reform Act. Statements about the commercial planning activities for Extina, planned sales force expansion; and financial guidance for 2004 are forward-looking statements. These statements are based on certain assumptions made by Connetics’ management based on experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Factors that could cause or contribute to such differences include, but are not limited to, risks and other factors that are discussed in documents filed by Connetics with the Securities and Exchange Commission from time to time, including Connetics’ Annual Report on form 10-K filed for the year ending December 31, 2003 and form 10-Q for the quarter ended June 30, 2004. Forward-looking statements represent the judgment of the Company’s management as of the date of this release, and Connetics disclaims any intent or obligation to update any forward-looking statements.

Company Contact:	Investor Relations:
Patrick O’Brien	Ina McGuinness or Bruce Voss
Director, Investor Relations	Lippert/Heilshorn & Associates
(650) 739-2950	(310) 691-7100
pobrien@connetics.com	imcguinness@lhai.com

# # #